Clinical Trial: This is a Phase II/III, Multicenter, Randomized, Active Comparator-controlled, Double-masked, Parallel-group, 96 Week Study to Investigate the Efficacy, Safety, Durability, and Pharmacokinetics of OCUL101 Administered to Patients With Neovascular AMD. There Will be Two Parts, Part A and Part B.

U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07520318) titled 'This is a Phase II/III, Multicenter, Randomized, Active Comparator-controlled, Double-masked, Parallel-group, 96 Week Study to Investigate the Efficacy, Safety, Durability, and Pharmacokinetics of OCUL101 Administered to Patients With Neovascular AMD. There Will be Two Parts, Part A and Part B.' on April 03.

Brief Summary: Oculgen has begun a study of an investigational drug called OCUL101 as a possible treatment for neovascular AMD. An investigational drug is one that has not been approved by regulatory agencies, such as the Food and Drug Administration (FDA) in the United States (US), the European Medicines Agency (EMA) in the Eu...